DDInter1840 DDInter32
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test . Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim .
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is upregulated by {v} (Compound) Afatinib
Trabectedin {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Afatinib
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) interacts with {v} (Gene) ABL1
ABL1 {u} (Gene) is bound by {v} (Compound) Afatinib
Trabectedin {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Afatinib
Trabectedin {u} (Compound) causes {v} (Side Effect) Connective tissue disorder
Connective tissue disorder {u} (Side Effect) is caused by {v} (Compound) Bedaquiline
Bedaquiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Afatinib
Trabectedin {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Nelfinavir
Nelfinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Afatinib
Trabectedin {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) interacts with {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Afatinib
Trabectedin {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Afatinib
Trabectedin {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) regulates {v} (Gene) KEAP1
KEAP1 {u} (Gene) is upregulated by {v} (Compound) Afatinib
Trabectedin {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) regulates {v} (Gene) ACOT9
ACOT9 {u} (Gene) is downregulated by {v} (Compound) Afatinib
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) is upregulated by Afatinib (Compound)
Trabectedin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Afatinib (Compound)
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) interacts with ABL1 (Gene) and ABL1 (Gene) is bound by Afatinib (Compound)
Trabectedin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Gefitinib (Compound) and Gefitinib (Compound) resembles Afatinib (Compound)
Trabectedin (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Bedaquiline (Compound) and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Afatinib
Trabectedin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Nelfinavir (Compound) and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Afatinib
Trabectedin (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) interacts with STUB1 (Gene) and STUB1 (Gene) is downregulated by Afatinib (Compound)
Trabectedin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Gefitinib (Compound) and Gefitinib (Compound) resembles Afatinib (Compound)
Trabectedin (Compound) binds SRC (Gene) and SRC (Gene) regulates KEAP1 (Gene) and KEAP1 (Gene) is upregulated by Afatinib (Compound)
Trabectedin (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) regulates ACOT9 (Gene) and ACOT9 (Gene) is downregulated by Afatinib (Compound)